Co-Diagnostics Free Cash Flow (FCF) History (CODX)

Co-Diagnostics reported −$29.8M in free cash flow for fiscal 2025, an increase of $66,423 from the previous fiscal year, with a free cash flow margin of −4793.17%.

View full Co-Diagnostics company overview

Co-Diagnostics free cash flow by year

Co-Diagnostics annual free cash flow

Fiscal yearPeriod endedFree cash flowChangeGrowthFCF margin
20252025-12-31−$29.8M$66,423−4793.17%
20242024-12-31−$29.9M−$6.5M−763.78%
20232023-12-31−$23.4M−$28.6M−344.20%
20222022-12-31$5.1M−$35.3M−87.28%+15.02%
20212021-12-31$40.4M$13.0M+47.54%+41.28%
20202020-12-31$27.4M$33.0M+36.74%
20192019-12-31−$5.6M−$1.5M−2622.80%
20182018-12-31−$4.1M−$780,665−10326.41%
20172017-12-31−$3.3M−$2.0M−43600.98%
20162016-12-31−$1.3M

Co-Diagnostics free cash flow growth trends

Over the last five reported fiscal years, free cash flow declined from $27.4M to −$29.8M, a net decrease of $57.2M. Co-Diagnostics's latest reported quarter, Q2 2026, generated −$7.2M in free cash flow, an increase of $1.5M year over year.

About the metric

What free cash flow means

Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.

Calculation and source

How free cash flow is calculated

TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.

Review Co-Diagnostics filings at SEC.gov ↗